Slow commercial adoption of ASTar
Revenue depends on hospitals validating and adopting a new testing workflow.
- Scope
- Consumables and instrument placements
- Materiality
- high
Q-Linea
Q-linea is a Swedish life-science diagnostics company focused on systems for rapid identification and antibiotic susceptibility testing of infectious diseases. Its core offering is the ASTar platform, which combines instruments, consumables, and service support for hospital laboratories and other healthcare providers.
82
11.07
9.94
| % | |
|---|---|
| ASTar instruments | 35% Capital sales or placement of ASTar diagnostic systems used in microbiology laboratories. |
| Consumables | 50% Recurring reagents and test consumables used with installed ASTar systems. |
| Service and maintenance | 10% Maintenance and support services for installed instruments and customer contracts. |
| Reagent rental | 5% Instrument placement model where revenue is earned through contracted consumable usage. |
Q-linea sells to healthcare providers, especially hospital laboratories that diagnose bloodstream and other serious...
- Hospital laboratoriesprimary
Buy ASTar systems and consumables to run rapid infectious-disease testing.
- Clinical sepsis care teamsprimary
Use test results to support faster, more targeted antibiotic treatment.
- Healthcare systems and reference labssecondary
Adopt the platform for workflow efficiency and recurring consumable use.
- Partners and distributorssecondary
Support sales in selected markets where Q-linea sells through partners.
Q-linea is headquartered in Sweden and serves healthcare customers worldwide through direct sales and partners...
- •Headquartered in Sweden
- •Sales made directly and via partners
- •Customer activity includes the United States
- •Global healthcare market exposure
- •Operations and reporting centered in SEK
Q-linea’s strategy is built around expanding adoption of ASTar and converting installed systems into recurring...
01
Expand ASTar commercializationshort-term
Installed instruments create the base for recurring consumables and service revenue.
02
Drive consumables pull-throughmedium-term
The business model expects most income to come from recurring consumable use.
03
Strengthen integrated diagnostics capabilitymedium-term
Reliable product performance and supply support are essential in clinical settings.
Q-linea is exposed to commercialization risk because adoption of a new diagnostic platform depends on clinical...
Product approval and regulatory risk
Diagnostics products require approvals and compliance before broad market use.
- Scope
- International commercialization
- Materiality
- high
R&D and clinical evidence risk
Clinical utility must be demonstrated to support adoption and reimbursement.
- Scope
- ASTar platform development
- Materiality
- high
Supply-chain and production risk
Instrument and consumable delivery depends on reliable manufacturing inputs.
- Scope
- Production and packaging
- Materiality
- medium
Currency and trade-barrier risk
The company sells internationally while reporting in SEK.
- Scope
- Foreign sales and procurement
- Materiality
- medium
Revenue recognition by contract type
Can shift revenue between periods
Warranty provisions
Affects liabilities and operating expense
Goodwill and acquired intangibles
Affects non-cash charges and carrying values
Fair value measurement of Level 3 assets
Affects balance-sheet values and gains/losses
: 11/08/2026